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Proteomics for Clinical Assessment of Kidney Disease
Alberto Ortiz
Kidney disease is one of the fastest growing causes of death worldwide,
disclosing an unmet clinical need for early diagnosis and optimized risk
stratiﬁcation that allows high risk patient selection for clinical trials and for
more intensive nephroprotective interventions in the clinic. The current issue
of PROTEOMICS—Clinical Applications contains four manuscripts that
explore diﬀerent aspects of clinical proteomics implementation in the context
of acute kidney injury, chronic kidney disease and, more speciﬁcally, diabetic
kidney disease, and kidney transplantation from a diagnostic and risk
stratiﬁcation point of view. Overall, the evidence discussed suggests that
chronic kidney disease is an example where clinical proteomics has become a
valuable tool ready for clinical implementation, expected to have a major
impact in patient management.
Kidney disease is one of the fastest growing causes of death
worldwide. Based on the Global Burden of Disease (GBD) study,
it was recently estimated that at the current rate of growth,
chronic kidney disease (CKD) would become the second cause of
death in Spain in the next decades, and Spanish data are not very
diﬀerent from those worldwide.[1,2] These estimates referred only
to CKD, deﬁned as evidence of kidney injury (e.g., pathological al-
buminuria or others) or decreased glomerular ﬁltration rate (be-
low 60mLmin−1 per 1.73m2) persisting formore than 3months,
with implications for health.[3] However, mortality due to acute
kidney injury (AKI) was not assessed by GBD. Currently, there
is no therapy for AKI beyond replacing renal function if required
andwhere it is available.[4,5] In this regard, CKD increases the risk
of cardiovascular death as well as of AKI.Moreover, renal replace-
ment therapy does not restoremortality risk in CKDpatients back
to baseline.[6] This is due to insuﬃcient replacement of just some
renal functions in the case of dialysis (e.g., production of the anti-
aging factor Klotho, which is lost early in the course of CKD, is
not replaced).[7] Kidney transplantation is a better option, but still
presents some issues such as clinical or subclinical kidney injury
due to rejection or nephrotoxicity. In this regard, major advances
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are required in the way we diagnose,
risk-stratify, and treat kidney disease
to change the current trend toward in-
creasing mortality from kidney disease.
Systems biology oﬀers the promise of
both improved risk stratiﬁcation and
diagnostic tools that allow a precision
medicine approach, as well as the
possibility to identify novel pathogenic
pathways and therapeutic targets. Of
the diverse systems biology techniques,
proteomics are closest to routine clinical
application for kidney diseases.[8,9] As
an example, laser dissection mass spec-
trometry is currently the best available
option to characterize the nature of
glomerular amyloidosis, a requirement
for etiology-targeted therapy.[10] In this issue of PROTEOMICS—
Clinical Applications, four manuscripts explore diﬀerent aspects
of clinical proteomics in the context of AKI, CKD, and kidn-
ey transplantation from a diagnostic and risk stratiﬁcation point
of view.[11–14] In this regard, another major application of pro-
teomics to kidney research, the identiﬁcation of novel pathogenic
pathways, is not speciﬁcally addressed.[15]
Klein and Schanstra explore the signiﬁcance of urine or kidney
proteomics biomarkers identiﬁed in animalmodels to the clinical
situation.[11] An exhaustive literature review identiﬁed 68 relevant
publications. However, they found little evidence that proteomic
biomarkers identiﬁed from preclinical studies had actual clinical
translation. In this regard, the availability of human urine allows
the direct noninvasive characterization of proteomic biomarkers
in human samples. The main interest of preclinical proteomic
studies lay in the evaluation of drug eﬃcacy and insights into
drug mechanisms of action. Thus, an ingenuity pathway analy-
sis using preclinical proteomics data from the literature identi-
ﬁed acute phase response signaling as the top canonical pathway
in AKI and cytoskeleton signaling in CKD, in accordance with
current concepts about their pathogenesis in humans. Of special
interest is the development of “humanized proteomic readouts”
for their use in drug assessment. These readouts combine pro-
teomic biomarkers shared by human and preclinical disease to
allow the evaluation of drugs of potential clinical interest in pre-
clinical models.
Persson and Rossing explore urinary proteomics in human
CKD.[12] Speciﬁcally, they focus on urinary proteomics using
capillary electrophoresis coupled to mass spectrometry (CE-MS),
a technique used to develop the CKD273 urine proteomics
classiﬁer. CKD273 has received a letter of support for CKD273
from the US Food and Drug Administration.[9] Persson and
Rossing review the available evidence regarding the potential
clinical use of CKD273 as a diagnostic and risk stratiﬁcation tool,
including the ongoing clinical trial Proteomic prediction and
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Of early diabetic nephRopathy in TYpe 2 diabetic participants
with normoalbuminuria (PRIORITY). Diabetic kidney disease
continues to be the main cause of CKD-associated mortality and
improved risk stratiﬁcation tools are required to identify patients
at highest risk of progression early in the course of the disease.[2]
PRIORITY has recruited 1777 participants, and 12.3% of these
have a high-risk urine CKD273 proteomics pattern.[16] These
high-risk patients were randomized to spironolactone or placebo
to test the hypothesis that urinary proteomics identiﬁcation of
high-risk patients may allow an intervention that prevents or
delays the progression to microalbuminuria. More recently, it
was shown that CKD273 may be optimized for the prediction
of rapid progression when glomerular ﬁltration rate in patients
without pathological albuminuria, that is, in those individuals
that similar to CKD patients, have a high risk of CKD progres-
sion, but that do not fulﬁll the current criteria to be diagnosed of
CKD.[17] This opens the door to future adjustments of the CKD
deﬁnition through the use of urinary proteomics criteria.
In an original study, Siwy et al. explore the value of CKD273
and urinary proteomics in a randomized clinical trial of an antidi-
abetic agent, the dipeptidyl peptidase-4 inhibitor linagliptin, in
diabetic kidney disease (MARLINA-T2D)(13). CKD273 indepen-
dently predicted CKD progression (i.e., annual eGFR decrease)
and allowed the stratiﬁcation of patients into high-risk and low-
risk of progression. Among high-risk patients, linagliptin pre-
vented a signiﬁcant loss of the renal function that was observed in
placebo-treated high-risk patients, while no diﬀerences were ob-
served in the overall cohort, illustrating the potential usefulness
of the biomarker in clinical trial design and enrichment in high
risk patients. Moreover, urinary proteomics disclosed a pattern
of dipeptidyl peptidase-4 inhibition that may be used to assess
compliance and monitor the intensity of therapy.
A further review by Marx et al. explores the application of
clinical proteomics for identiﬁcation of molecular pathways spe-
ciﬁc for diverse, clinically relevant forms of kidney allograft
disease such as antibody-mediated rejection, T cell-mediated
rejection, interstitial ﬁbrosis and tubular atrophy, and poly-
oma virus-associated nephropathy.[14] A well-designed clinical
proteomics may be used for noninvasive monitoring and se-
lection of patients that need renal biopsy for adjustment of
therapy.
In summary, the current issue of PROTEOMICS—Clinical
Applications provides an overview of the state-of-the-art of clini-
cal proteomics in kidney disease, both through a review of avail-
able information regarding the impact of preclinical models and
urinary proteomics and through novel data on the possibilities
oﬀered by urinary proteomics for risk stratiﬁcation and design of
clinical trials. CKD is an example where clinical proteomics eﬀec-
tively delivered, a demonstrator how to evolve from basic science
to developing a valuable tool ready for clinical implementation,
is expected to have a major impact in patient management.
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